These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9717825

  • 1. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
    Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF.
    Clin Cancer Res; 1998 Aug; 4(8):1955-63. PubMed ID: 9717825
    [Abstract] [Full Text] [Related]

  • 2. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
    Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M.
    Clin Cancer Res; 1999 Jul; 5(7):1758-66. PubMed ID: 10430080
    [Abstract] [Full Text] [Related]

  • 3. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
    Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS.
    Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
    [Abstract] [Full Text] [Related]

  • 4. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.
    Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J.
    Cancer Res; 1992 Sep 01; 52(17):4587-90. PubMed ID: 1511426
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.
    Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638
    [Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA.
    Clin Cancer Res; 2002 Sep 01; 8(9):2856-61. PubMed ID: 12231527
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ.
    Cancer; 2008 Nov 01; 113(9):2504-11. PubMed ID: 18825661
    [Abstract] [Full Text] [Related]

  • 9. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Nov 01; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 10. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia.
    Kornblau SM, Chen N, del Giglio A, O'Brien S, Deisseroth AB.
    Cancer Res; 1994 Jan 01; 54(1):242-6. PubMed ID: 8261446
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
    Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F.
    Haematologica; 2002 Mar 01; 87(3):250-6. PubMed ID: 11869936
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX.
    Ai Zheng; 2006 Aug 01; 25(8):1007-12. PubMed ID: 16965684
    [Abstract] [Full Text] [Related]

  • 13. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
    Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G, Acute Leukemia Working Party of the GIMEMA group.
    Haematologica; 2008 Jul 01; 93(7):1017-24. PubMed ID: 18508799
    [Abstract] [Full Text] [Related]

  • 14. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
    Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C.
    Clin Cancer Res; 2004 Jun 01; 10(11):3737-44. PubMed ID: 15173080
    [Abstract] [Full Text] [Related]

  • 15. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
    Daneshbod Y, Amirghofran Z, Tabei SZ.
    Neoplasma; 2005 Jun 01; 52(2):109-14. PubMed ID: 15800708
    [Abstract] [Full Text] [Related]

  • 16. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z.
    Int J Hematol; 1999 Dec 01; 70(4):248-60. PubMed ID: 10643151
    [Abstract] [Full Text] [Related]

  • 17. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
    Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M.
    Cancer; 2003 May 01; 97(9):2212-7. PubMed ID: 12712473
    [Abstract] [Full Text] [Related]

  • 18. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H.
    Eur J Haematol; 2004 Feb 01; 72(2):89-106. PubMed ID: 14962246
    [Abstract] [Full Text] [Related]

  • 19. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H.
    Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664
    [Abstract] [Full Text] [Related]

  • 20. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.
    Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.